TABLE 1.
Demographic, Clinical and Laboratory Data of COVID-19 Patients Treated With CPAP and PP
| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gender | M | M | M | M | M | M | M | F | M | M | F | M | M |
| Age (y) | 69 | 72 | 73 | 68 | 65 | 65 | 59 | 44 | 65 | 69 | 74 | 68 | 70 |
| BMI | 30 | 18 | 27 | 35 | 22 | 33 | 33 | 23 | 29 | 31 | 26 | 38 | 39 |
| Coexisting chronic diseases * | AF, COPD | AH, DM, Asthma | AH | AH, Dyslipemia Hyperuricemia | AH, CHD AF, Anemia DM | AH | AH | N/A | AH, DM, Dyslipemia | Myasthenia gravis | AH | AH | AH, AF |
| Time from symptom onset to admission (d) | 7 | 7 | 7 | 3 | 7 | 5 | 7 | 8 | 7 | 7 | 7 | 5 | 10 |
| Time from admission to CPAP (d) | 1 | 0 | 4 | 0 | 4 | 1 | 3 | 0 | 3 | 5 | 1 | 2 | 1 |
| Time from CPAP to first PP (d) | 3 | 2 | 1 | 1 | 0 | 2 | 3 | 1 | 0 | 0 | 1 | 1 | 1 |
| ET | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | No | Yes | Yes | No |
| Time from first PP to ET (d) | 4 | 1 | 3 | 0 | 0 | 1 | 2 | N/A | N/A | N/A | 9 | 0 | N/A |
| Total number of PP before ET | 4 | 1 | 6 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 8 | 1 | 3 |
| Time from admission to ET (d) | 8 | 4 | 8 | 1 | 4 | 4 | 8 | N/A | N/A | N/A | 11 | 3 | N/A |
| Respiratory rate before first PP | 38 | 32 | 24 | 28 | 48 | 20 | 38 | 24 | 40 | 40 | 18 | 24 | 34 |
| Respiratory rate after first PP | 30 | 21 | 24 | 24 | 48 | 20 | 30 | 32 | 40 | 40 | 18 | 26 | 28 |
| PaO2:FiO2 ** before first PP | 121 | 101 | 108 | 98 | 136 | 121 | 113 | 145 | 118 | 114 | 109 | 109 | 105 |
| PaO2:FiO2 after first PP | 126 | 138 | 130 | 101 | 230 | 178 | 230 | 350 | 178 | 162 | 126 | 98 | 116 |
| Time in PP *** (h) | 2 | 2 | 3.5 | 2 | 0.75 | 3 | 3 | 3 | 2 | 1 | 2.5 | 3.5 | 3 |
| SOFA score | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 | 4 | 3 | 4 | 4 | 4 |
|
WBC count /x mmc before first PP
n.r 4000-10.000 |
11 900 | 12 340 | 6840 | 19 830 | 12 310 | 13 010 | 9120 | 10 570 | 4090 | 7440 | 4934 | 8080 | 13 600 |
| Lymphocyte count x mmc before first PP n.r 1000-3400 | 631 | 629 | 588 | 674 | 566 | 390 | 1368 | 1216 | 540 | 841 | 1030 | 517 | 666 |
| Lymphocyte % n.r 19-48% | 5.3% | 5.1% | 8.6% | 3.4% | 4.6% | 3% | 15% | 11.5% | 13.2% | 11.3% | 16.1% | 6.4% | 4.9% |
| D-dimer ug/L before first PP n.r <70 | 980 | 1598 | 1190 | 10 966 | 25 495 | 3667 | 3414 | 1665 | 980 | 1268 | 683 | 312 | 336 |
| Complications of PP | None | None | None | None | None | None | None | None | None | None | None | None | None |
| Outcome | Discharged | Dead | Dead | Dead | Dead | Dead | Dead | Discharged | Discharged | Discharged | Dead | Discharged | Discharged |
*
Abbreviations: COVID-19: coronavirus disease 2019; M: male; F: female; BMI: body mass index, calculated as weight in kilograms divided by height in meters squared; COPD: chronic obstructive pulmonary disease; AF: atrial fibrillation; DM: diabetes mellitus; CHD: coronary heart disease; AH: arterial hypertension. NR: normal range; CPAP: continuous positive airway pressure, PP: prone position, ET: endotracheal intubation.
**
The normal PaO2:FIO2 ratio is more than 400 mm Hg; if PaO2:FIO2 less than 300 mm Hg indicates acute respiratory distress syndrome.
***
For patients with more than one PP cycle, time is expressed as the mean time in PP.